Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Becton Dickinson (BDX) Meets Q1 Earnings Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.00% and -0.05%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.
AmerisourceBergen (ABC) Jumps: Stock Rises 6.2%
by Zacks Equity Research
AmerisourceBergen (ABC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Why the Earnings Surprise Streak Could Continue for Becton Dickinson (BDX)
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Varian Strong on Global Expansion and Proton Therapy Arm
by Zacks Equity Research
Varian's (VAR) strong presence in China instills optimism in the stock.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.
Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up
by Zacks Equity Research
Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.
CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
CONMED's (CNMD) Q4 results get a boost from solid segmental performances.
Here's Why Investors Should Bet on Abiomed (ABMD) Stock Now
by Zacks Equity Research
Strong contribution from Impella product line is likely to provide Abiomed (ABMD) a competitive edge in the MedTech space.
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Becton, Dickinson and Company, ArcBest, Tetra Tech and Nexstar Media
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Becton, Dickinson and Company, ArcBest, Tetra Tech and Nexstar Media
5 Cheap Dividend Stocks That Offer Growth
by Sweta Killa
Amid heightened volatility and uncertainty, investors are looking for both income and growth in their portfolio. As a result, picking dividend growth stocks appear as a winning strategy.
Here's Why Investors Should Hold AngioDynamics (ANGO) Now
by Zacks Equity Research
AngioDynamics' (ANGO) flagship NanoKnife System is currently witnessing robust demand.
Cerner Picked by Remi Vista for Behavioral Health Technology
by Zacks Equity Research
Apart from Cerner Integrated, Cerner's (CERN) revenue cycle solutions will help Remi Vista's financial operations.
Here's Why Investors Should Retain athenahealth (ATHN) Stock
by Zacks Equity Research
athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.
Allscripts Selected by Premier for Connected Health Platform
by Zacks Equity Research
Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.
Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up
by Zacks Equity Research
Cerner's (CERN) coveted Millennium platform has seen rising demand in recent times.
Here's Why You Should Invest in OPKO Health (OPK) Right Now
by Zacks Equity Research
OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.
Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA
by Zacks Equity Research
Becton, Dickinson's (BDX) Diagnostic Systems portfolio lends it a competitive edge.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Plethora of developments for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.
BD Gets Enterprise Level Cybersecurity Assessment From UL
by Zacks Equity Research
BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.
Why Is Becton Dickinson (BDX) Up 3.4% Since Last Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stock Market News For Nov 30, 2018
by Zacks Equity Research
Wall Street ended lower on Thursday as investors closely watched the G-20 summit in Argentina where President Donald Trump is scheduled to discuss trade issues with his Chinese counterpart Xi Jinping
BD Brings HealthSight Diversion App to Combat Opioid Crisis
by Zacks Equity Research
BD's (BDX) latest development is likely to boost the company's Medication Management unit.